These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 15993080

  • 1. 8-Azapurines as new inhibitors of cyclin-dependent kinases.
    Havlicek L, Fuksova K, Krystof V, Orsag M, Vojtesek B, Strnad M.
    Bioorg Med Chem; 2005 Sep 15; 13(18):5399-407. PubMed ID: 15993080
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Biaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part I.
    Trova MP, Barnes KD, Barford C, Benanti T, Bielaska M, Burry L, Lehman JM, Murphy C, O'Grady H, Peace D, Salamone S, Smith J, Snider P, Toporowski J, Tregay S, Wilson A, Wyle M, Zheng X, Friedrich TD.
    Bioorg Med Chem Lett; 2009 Dec 01; 19(23):6608-12. PubMed ID: 19846305
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.
    Gucký T, Jorda R, Zatloukal M, Bazgier V, Berka K, Řezníčková E, Béres T, Strnad M, Kryštof V.
    J Med Chem; 2013 Aug 08; 56(15):6234-47. PubMed ID: 23829517
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death.
    Ferguson M, Luciani MG, Finlan L, Rankin EM, Ibbotson S, Fersht A, Hupp TR.
    Cell Cycle; 2004 Jan 08; 3(1):80-9. PubMed ID: 14657672
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor.
    Krystof V, McNae IW, Walkinshaw MD, Fischer PM, Müller P, Vojtesek B, Orság M, Havlícek L, Strnad M.
    Cell Mol Life Sci; 2005 Aug 08; 62(15):1763-71. PubMed ID: 16003486
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
    David-Pfeuty T.
    Oncogene; 1999 Dec 09; 18(52):7409-22. PubMed ID: 10602500
    [Abstract] [Full Text] [Related]

  • 18. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
    Akiyama T, Yoshida T, Tsujita T, Shimizu M, Mizukami T, Okabe M, Akinaga S.
    Cancer Res; 1997 Apr 15; 57(8):1495-501. PubMed ID: 9108451
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and biological evaluation of guanidino analogues of roscovitine.
    Dolečková I, Cesnek M, Dračinský M, Brynda J, Voller J, Janeba Z, Kryštof V.
    Eur J Med Chem; 2013 Apr 15; 62():443-52. PubMed ID: 23399722
    [Abstract] [Full Text] [Related]

  • 20. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
    Iseki H, Ko TC, Xue XY, Seapan A, Hellmich MR, Townsend CM.
    Surgery; 1997 Aug 15; 122(2):187-94; discussion 194-5. PubMed ID: 9288122
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.